Professional Documents
Culture Documents
Presented By: Moderator: Dr. Vikas Kumar
Presented By: Moderator: Dr. Vikas Kumar
VIKAS KUMAR
MODERATOR : DR.P.K.PURI
(HOD DEPTT. OF UROLOGY,IGMC,
SHIMLA)
INTRODUTION
•Bladder cancer is the 9th most common cancer overall and 2nd after
prostate ca in genitourinary sys.
In North America and Europe, 95% to 97% of cases are urothelial
carcinoma;
in Africa 60% to 90% are urothelial and 10% to 40% are
squamous cell; and
Egypt has the highest rate of squamous cell carcinoma because of
the endemic infections with Schistosoma species .
Bladder cancer is 3 times more common in men than in
women.
I) GENETIC
- The null GSTM1 polymorphism is
associated with an increased bladder risk with
a relative risk of 1.5.
- The slow NAT-2 polymorphism is
related to bladder cancer with an odds ratio of
1.4 compared with the fast polymorphism
II) EXTERNAL RISK FACTORS
i) Smoking – 60-70%
v) Radiation
vi) Chemotherapy
vii) Heredity
PATHOLOGY
Histologically, 90% of bladder cancers are of urothelial origin, 5%
are squamous cell carcinomas, and less than 2% are
adenocarcinoma or other variants.
Group T N M
Stage 0a Ta N0 M0
Stage 0is Tis N0 M0
Stage I T1 N0 M0
Stage II T2a N0 M0
T2b N0 M0
Stage III T3a N0 M0
T3b N0 M0
T4a N0 M0
Stage IV T4b N0 M0
Any T N1-3 M0
Any T Any N M1
DISSEMINATION
A) Angiolymphatic Invasion : seen in approximately 25% of invasive
urothelial carcinoma.
specificity of 85% for papillary tumors but is relatively poor for CIS
(15%).
-This may improve the detection of small papillary lesions and CIS.
BTA stat 70 75
BTAtrak 69 65
NMP22 73 80
FDP 61 79
ImmunoCyt 83 80
Cytometry 60 80
Quanticyt 59 79
Hb-dipstick 52 82
Lewis X 83 85
FISH 84 95
Telomerase 75 86
Microsatellite 91 94
CYFRA21-1 94 86
UBC 78 91
Cytokeratin 20 91 84
BTA 50 86
TPS 72 78
NON–MUSCLE-INVASIVE BLADDER
CANCER
+/- CIS
Tumor Size
Multiplicity
Papillary vs Sessile
1) Bacillus Calmette-Guérin
ASSESSMENT
Possible urine culture to rule out bacterial urinary tract infection
SYMPTOM MANAGEMENT
ASSESSMENT
Urine culture, chest radiograph, liver function tests
MANAGEMENT
Consult immediately with physician experienced in
management of mycobacterial infections/complications.
Bropirimine
Interleukin-12
INTRAVESICAL CHEMOTHERAPY
INDICATIONS
Multifocal tumor
Recurrences > 4
CIS
Intravesical chemotherapy has a clear impact on tumor
recurrence when immediately instilled after TURBT and in
the adjuvant setting.
Given for 6-8 wks post op. but response not better than
BCG
Various chemotherapeutic agents
include:
Mitomycin C
Doxorubicin and Its Derivatives
Thiotepa
Gemcitabine and
Taxanes
EARLY CYSTECTOMY
• Should be considered in patients
-Micropapillary Variant
– Do not tolerate intravesical therapy
– Failed attempts at disease control with TURBT +IVT
– Lesions not amenable to endoscopic resection
– Failure of TURBT and intravesical therapy
• Recurrence at higher grade and multifocality
• Progression on intravesical therapy (Grade Progression)
• Invasion into detrusor (T progression)
• Especially in HGTa or CIS
RADIATION THERAPY
creatinine,
electrolytes,
CXR
Bone scan
MRI
PET
Midline incision
Thorough intraabdominal exploration (rule out
metastatic disease)
Assess resectability of bladder
Step 1: mobilize the urachus from the umbilicus
Step 2: mobilize the bladder from the bowel
Step 3: isolate and transect ureters
Step 4: complete lymph node dissection
Step 5: separate bladder from sigmoid colon
Step 6: complete posterior dissection and cut off bladder blood supply
Step 7: complete anterior dissection and isolate urethra
Step 8: transect urethra and remove specimen
Cystectomy is not performed when
Therapeutic benefit
Removal of micrometastatic disease
Pelvic Lymphadenectomy
Socially-acceptable continence
Empties completely
Natural peristalsis of
intestine propels urine
through the segment Ileum
ureter
Other end is brought ureter
out through an opening
on the abdomen
Ileal Conduit
ADVANTAGES DISADVANTAGES
Simplest to perform Need to wear an external
Least potential for collection bag
complications Stoma complications
No need for intermittent Parastomal hernia
catheterization Stomal stenosis
Appendix
removed
Right colon
and distal
ileum Right colon is
isolated opened
lengthwise
and folded
down to
create a
sphere
Continent Cutaneous Reservoir
INDIANA POUCH
EFFERENT LIMB
RESERVOIR (to skin)
Continence
maintained by
ileocecal valve
Continent Cutaneous Reservoir
ADVANTAGES DISADVANTAGES
No external bag Most complex
Stoma can be covered Need for regular
with bandaid intermittent
catheterization
Potential complications:
Stoma stenosis
Stones
Urine infections
Orthotopic Neobladder
Currently the diversion of choice
Studer, T-Pouch, Hautmann, Ghoniem, etc.
COMPONENTS:
Internal reservoir – detubularized ileum
Ureters
attache
d
15-20 cm
44 cm Ileum
detubularize
d Reservoir
Connect to urethra
22 cm
22 cm
15-20 cm
Orthotopic Neobladder
Afferent Limb
Detubularization of ileum
Orthotopic Neobladder
Opening to
urethra
Orthotopic Neobladder
ADVANTAGES DISADVANTAGES
No external bag Incontinence (10-
Surgeon Factors
Familiarity with various types of diversions
Urinary Diversions
Enterostomal therapist is CRITICAL for success
Criteria
a) Same as for TURBT plus
TURBT + CHEMO + RT
Criteria
a) clinical stage (organ-confined),
b) tumor size less than 3 to 5 cm,
c) absence of hydronephrosis,
d) absence of a palpable mass, and
e) unifocal disease
Role of neoadjuvant
chemotherapy
Chemotherapy before surgery has several advantages.
DISADVANTAGE
ADVANTAGES